FLUORETH-LAD

FLUORETH-LAD (TRALA-15), or FE-LAD, also known as 6-(2-fluoroethyl)-LAD or 6-(2-fluoroethyl)-6-nor-LSD, is a lysergamide derivative.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

FLUORETH-LAD (TRALA-15), or FE-LAD, also known as 6-(2-fluoroethyl)-LAD or 6-(2-fluoroethyl)-6-nor-LSD, is a lysergamide derivative. It was first proposed by Alexander and Ann Shulgin in their book TiHKAL, but was never synthesised by Shulgin.

Synthesis and activity data for the compound were first reported in a 2022 patent by Matthias Grill, in which pharmacological testing showed it to have similar affinity to LSD at some targets such as the 5-HT 1A and 5-HT 2A serotonin receptors, but much lower affinity at other targets such as 5-HT 2C and at dopamine receptors, giving it comparatively greater selectivity compared to LSD. Currently new lysergamide derivates are in the development phase at MiHKAL GmbH in Switzerland.

See also

Substituted lysergamide FP-LAD CE-LAD AL-LAD ETH-LAD PRO-LAD

FLUORETH-LAD (TRALA-15) - Isomer Design

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377226583 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.